Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
11:34am, Tuesday, 07'th Apr 2026
New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm,
NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR). Shareholders who purchased shares of NKTR during the class
New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
11:50am, Monday, 06'th Apr 2026
LOS ANGELES, April 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
08:51am, Monday, 06'th Apr 2026
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
04:14am, Monday, 06'th Apr 2026
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10
New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 2
New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 03'rd Apr 2026
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar T
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
10:55am, Friday, 03'rd Apr 2026
LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
10:00am, Thursday, 02'nd Apr 2026
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers.
